DP
ARCT icon

Diadema Partners’s Arcturus Therapeutics ARCT Stock Holding History

Diadema Partners’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-150,900
Closed -$2.78M – 154
2025
Q3 		$2.78M Buy
+150,900
New +$2.42M 0.71% 47

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Diadema Partners's ARCT Position: Q4 2025 in Review

Diadema Partners sold out of Arcturus Therapeutics (ARCT) in Q4 2025, closing a stake of 48,811 shares — an estimated $900K sold.

Diadema Partners first reported a position in ARCT in Q3 2025 and held it in 1 quarter. The position peaked at $900K in Q3 2025. 120 funds tracked by Wall St. Rank hold ARCT as of Q4 2025.

  • Diadema Partners reported no remaining Arcturus Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Diadema Partners sold 48,811 Arcturus Therapeutics shares in Q4 2025, an estimated $900K.
  • Diadema Partners first reported a position in Arcturus Therapeutics in Q3 2025 and held it in 1 quarter.
  • Diadema Partners's Arcturus Therapeutics position peaked at $900K in Q3 2025.
  • 120 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q4 2025.

Based on Diadema Partners's 13F filing for Q4 2025, filed 17 Feb 2026.